Research Articles - Macular Degeneration
Acucela Inc., a Seattle-based developer of eye-disease therapies, is enrolling 440 patients across 56 sites for its three-year, Phase 2b/3 clinical trial of emixustat hydrochloride (formerly ACU-4429) for the treatment of advanced dry age-related macular degeneration (AMD), a vision-robbing retinal condition also known as geographic atrophy (GA). In August, the company reported that it reached 50 percent enrollment for the study.
A new study published in the journal Ophthalmology indicates that the beneficial effects of Lucentis, a popular treatment for wet age-related macular degeneration (AMD) developed by Genentech, may diminish over time for some patients. While Lucentis stabilized or improved vision in 90 percent of people with wet AMD participating in two-year clinical trials, study results
A research team from Germany and the Netherlands found that people from their countries who reported having allergies had a significantly reduced risk for age-related macular degeneration (AMD). Results of the study, which involved 3,585 Caucasian individuals, were reported in the journal Investigative Ophthalmology & Visual Science. The study was led
Dr. Stephen Rose
- An international collaboration of more than 150 researchers from 18 institutions has identified seven new genetic regions — also known as loci — linked to the risk for developing age-related macular degeneration (AMD). While this discovery implicates seven specific genes, further research is needed to definitively establish the genes’ connection to the disease.
The study, funded in part by the Foundation Fighting Blindness, is the largest genome-wide study for AMD, and will help scientists find new targets for
- The biopharmaceutical company Regeneron has received FDA approval for Eylea™, its treatment for wet age-related macular degeneration (AMD) that is as effective as currently prescribed wet AMD therapies such as Lucentis® but requires less-frequent ocular injections.
“Fewer injections with Eylea should translate to reduced risk of injection-related discomfort and complications for patients while not
- The National Eye Institute (NEI) reports that second-year results from its Comparison of AMD Treatments Trial (CATT) show that Lucentis and Avastin are similarly safe and effective in halting and reversing vision loss for people with wet age-related macular degeneration (AMD). The second-year CATT results, published on April 30, 2012, in the journal Ophthalmology, are consistent with
An innovative, targeted search technique known as whole-exome sequencing is dramatically reducing the time, effort and expense it takes to discover genetic defects that cause retinal disease. While the increasing raw power of genetic-screening technologies is continually accelerating the pace of gene discoveries, the whole-exome search strategy is a major leap forward.